Profile data is unavailable for this security.
About the company
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
- Revenue in PLN (TTM)14.81m
- Net income in PLN-59.30m
- Incorporated2009
- Employees204.00
- LocationMabion SAgen. Mariana Langiewicza 60KONSTANTYNOW LODZKI 95-050PolandPOL
- Phone+48 422077890
- Fax+48 422032703
- Websitehttps://www.mabion.eu/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicofarma Biotech SA | 281.45k | -3.06m | 32.43m | 24.00 | -- | 6.81 | -- | 115.21 | -0.0450 | -0.0450 | 0.0041 | 0.07 | 0.0199 | 66.64 | 0.7469 | 11,727.08 | -21.55 | -14.96 | -31.48 | -18.59 | 38.80 | 36.02 | -1,085.51 | -64.02 | 0.821 | -11.71 | 0.00 | -- | 63.14 | -17.39 | 33.11 | -- | -- | -- |
| Sds Optic SA | 3.02m | -3.02m | 37.55m | 41.00 | -- | 31.15 | -- | 12.42 | -0.5058 | -0.5058 | 0.5020 | 0.1913 | 0.179 | 20.36 | 12.25 | -- | -17.98 | -31.44 | -18.90 | -34.79 | 91.17 | 57.78 | -100.39 | -122.69 | 2.42 | -2.51 | -- | -- | -31.78 | 303.14 | 40.23 | -- | -- | -- |
| Sygnis SA | 9.81m | 2.56m | 43.34m | 12.00 | 14.05 | 1.25 | 9.51 | 4.42 | 0.1124 | 0.1124 | 0.4315 | 1.26 | 0.1813 | 0.4305 | 3.21 | -- | 4.72 | -6.31 | 6.82 | -8.93 | 88.66 | 64.29 | 26.06 | -30.82 | 0.9722 | 5.62 | 0.126 | -- | 30.62 | 28.56 | 122.65 | 53.12 | -- | -- |
| Read Gene SA | 15.57m | 808.32k | 63.43m | 11.00 | 73.96 | 16.59 | 50.37 | 4.07 | 0.0727 | 0.0727 | 1.39 | 0.3243 | 1.04 | 10.34 | 4.23 | -- | 5.38 | -1.82 | 5.97 | -2.00 | 93.56 | 91.12 | 5.19 | -2.66 | 7.52 | 3.15 | -- | -- | 17.67 | 20.73 | 172.75 | 18.28 | 37.45 | -- |
| Genomtec SA | 15.00k | -11.01m | 73.74m | -- | -- | 7.13 | -- | 4,916.09 | -0.7485 | -0.7485 | 0.001 | 0.6869 | 0.0009 | -- | 0.0143 | -- | -65.47 | -89.96 | -82.11 | -113.38 | -54,120.00 | -4,379.72 | -73,393.34 | -17,225.07 | 2.82 | -39.82 | 0.1409 | -- | 0.00 | -63.42 | -24.35 | -- | -34.54 | -- |
| Urteste SA | 0.00 | -5.47m | 77.83m | 34.00 | -- | 3.32 | -- | -- | -3.88 | -3.88 | 0.00 | 15.35 | 0.00 | -- | -- | -- | -15.56 | -29.65 | -18.99 | -31.35 | -- | -45,933.33 | -- | -623,333.30 | -- | -- | 0.0128 | -- | -- | -- | 35.00 | -- | 197.79 | -- |
| Hyenergy SA | 3.29m | 169.85k | 77.91m | 27.00 | -- | 3.95 | 318.90 | 23.69 | -0.0936 | -0.0936 | 0.1654 | 0.5878 | 0.1821 | 0.1259 | 0.7741 | -- | 0.9403 | 2.39 | 1.28 | 3.35 | 99.70 | 77.46 | 5.16 | 3.11 | 1.30 | 1.17 | 0.00 | -- | 192.83 | 19.47 | 100.30 | -- | -45.79 | -- |
| Nanogroup SA | -6.90k | -6.93m | 83.71m | -- | -- | 7.18 | -- | -- | -0.1844 | -0.1844 | -0.0002 | 0.3553 | -0.0003 | 2.64 | -- | -- | -30.59 | -29.50 | -51.55 | -33.80 | -- | 66.72 | -- | -2,258.26 | 0.9785 | -464.18 | 0.00 | -- | 3.96 | -64.09 | 34.50 | -- | 3.07 | -- |
| Poltreg SA | 0.00 | -24.56m | 114.72m | 33.00 | -- | 2.32 | -- | -- | -5.27 | -5.27 | 0.00 | 10.61 | 0.00 | 16.45 | -- | 0.00 | -25.87 | -9.02 | -29.62 | -10.18 | -- | -659.36 | -- | -854.23 | 2.65 | -- | 0.1365 | -- | -74.98 | -6.89 | -38.06 | -- | 83.47 | -- |
| Mabion SA | 14.81m | -59.30m | 130.91m | 204.00 | -- | 1.87 | -- | 8.84 | -3.67 | -3.67 | 0.9164 | 4.33 | 0.0988 | 8.10 | 27.25 | 72,602.94 | -39.56 | 0.5366 | -54.81 | 1.06 | -178.55 | 58.34 | -400.37 | 0.9643 | 0.2276 | -- | 0.04 | -- | -54.50 | -- | -115.35 | -- | 6.00 | -- |
| Molecure SA | 5.11m | -24.42m | 150.40m | 71.00 | -- | 1.68 | -- | 29.42 | -1.20 | -1.20 | 0.2493 | 4.34 | 0.0553 | -- | 7.01 | 50,119.41 | -26.42 | -3.15 | -27.53 | -3.30 | 51.48 | 93.34 | -477.67 | -15.45 | -- | -- | 0.0588 | -- | -40.47 | 278.20 | -10.27 | -- | 12.49 | -- |
| BIOTON SA | 295.81m | -2.82m | 358.91m | 363.00 | -- | 0.6062 | 10.15 | 1.21 | -0.0329 | -0.0329 | 3.45 | 6.90 | 0.3814 | 2.02 | 8.84 | 814,906.30 | -0.3638 | 0.5935 | -0.4325 | 0.7338 | 29.69 | 41.35 | -0.954 | 2.47 | 0.5186 | 1.64 | 0.0682 | 0.00 | 14.38 | 0.561 | -788.26 | -- | -26.87 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Generali PTE SAas of 31 Dec 2024 | 358.96k | 2.22% |
| AgioFunds TFI SAas of 28 Jan 2026 | 92.66k | 0.57% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 416.00 | 0.00% |
| Investors TFI SAas of 30 Jun 2025 | 0.00 | 0.00% |
